The albumin in acute stroke part 1 trial: An exploratory efficacy analysis

Michael D. Hill, Renee H. Martin, Yuko Y. Palesch, Diego Tamariz, Bonnie D. Waldman, Karla J. Ryckborst, Claudia S. Moy, William G. Barsan, Myron Ginsberg

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background And Purpose- The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial. Methods- ALIAS is a multicenter, blinded, randomized controlled trial. Data on 434 subjects, comprising the ALIAS Part 1 subjects, were analyzed. We examined both the thrombolysis and nonthrombolysis cohorts combined and separately in a "target population" by excluding subjects who would not have been eligible for the ALIAS Part 2 Trial; the latter comprised patients >83 years of age, those with elevated baseline troponin values, and those with in-hospital stroke. We examined the differences in the primary composite outcome, defined as a modified Rankin Scale score of 0 to 1 and/or a National Institutes of Health Stroke Scale score of 0 to 1 at 90 days after randomization. Results- In the combined thrombolysis plus nonthrombolysis cohorts of the target population, 44.7% of subjects in the ALB group had a favorable outcome compared with 36.0% in the saline group (absolute effect size=8.7%; 95% CI, -2.2% to 19.5%). Among thrombolyzed subjects of the target population, 46.7% had a favorable outcome in the ALB group compared with 36.6% in the saline group (absolute effect size=10.1%; 95% CI, -2.0% to 20.0%). Conclusions- Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results.

Original languageEnglish
Pages (from-to)1621-1625
Number of pages5
JournalStroke
Volume42
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Albumins
Stroke
Health Services Needs and Demand
Troponin
National Institutes of Health (U.S.)
Random Allocation
Randomized Controlled Trials

Keywords

  • acute treatment
  • adjuvant stroke therapy
  • ischemic stroke albumin
  • neuroprotection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Hill, M. D., Martin, R. H., Palesch, Y. Y., Tamariz, D., Waldman, B. D., Ryckborst, K. J., ... Ginsberg, M. (2011). The albumin in acute stroke part 1 trial: An exploratory efficacy analysis. Stroke, 42(6), 1621-1625. https://doi.org/10.1161/STROKEAHA.110.610980

The albumin in acute stroke part 1 trial : An exploratory efficacy analysis. / Hill, Michael D.; Martin, Renee H.; Palesch, Yuko Y.; Tamariz, Diego; Waldman, Bonnie D.; Ryckborst, Karla J.; Moy, Claudia S.; Barsan, William G.; Ginsberg, Myron.

In: Stroke, Vol. 42, No. 6, 01.06.2011, p. 1621-1625.

Research output: Contribution to journalArticle

Hill, MD, Martin, RH, Palesch, YY, Tamariz, D, Waldman, BD, Ryckborst, KJ, Moy, CS, Barsan, WG & Ginsberg, M 2011, 'The albumin in acute stroke part 1 trial: An exploratory efficacy analysis', Stroke, vol. 42, no. 6, pp. 1621-1625. https://doi.org/10.1161/STROKEAHA.110.610980
Hill MD, Martin RH, Palesch YY, Tamariz D, Waldman BD, Ryckborst KJ et al. The albumin in acute stroke part 1 trial: An exploratory efficacy analysis. Stroke. 2011 Jun 1;42(6):1621-1625. https://doi.org/10.1161/STROKEAHA.110.610980
Hill, Michael D. ; Martin, Renee H. ; Palesch, Yuko Y. ; Tamariz, Diego ; Waldman, Bonnie D. ; Ryckborst, Karla J. ; Moy, Claudia S. ; Barsan, William G. ; Ginsberg, Myron. / The albumin in acute stroke part 1 trial : An exploratory efficacy analysis. In: Stroke. 2011 ; Vol. 42, No. 6. pp. 1621-1625.
@article{e8245737df4f4f0daf1607f673dfa1ba,
title = "The albumin in acute stroke part 1 trial: An exploratory efficacy analysis",
abstract = "Background And Purpose- The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25{\%} human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial. Methods- ALIAS is a multicenter, blinded, randomized controlled trial. Data on 434 subjects, comprising the ALIAS Part 1 subjects, were analyzed. We examined both the thrombolysis and nonthrombolysis cohorts combined and separately in a {"}target population{"} by excluding subjects who would not have been eligible for the ALIAS Part 2 Trial; the latter comprised patients >83 years of age, those with elevated baseline troponin values, and those with in-hospital stroke. We examined the differences in the primary composite outcome, defined as a modified Rankin Scale score of 0 to 1 and/or a National Institutes of Health Stroke Scale score of 0 to 1 at 90 days after randomization. Results- In the combined thrombolysis plus nonthrombolysis cohorts of the target population, 44.7{\%} of subjects in the ALB group had a favorable outcome compared with 36.0{\%} in the saline group (absolute effect size=8.7{\%}; 95{\%} CI, -2.2{\%} to 19.5{\%}). Among thrombolyzed subjects of the target population, 46.7{\%} had a favorable outcome in the ALB group compared with 36.6{\%} in the saline group (absolute effect size=10.1{\%}; 95{\%} CI, -2.0{\%} to 20.0{\%}). Conclusions- Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results.",
keywords = "acute treatment, adjuvant stroke therapy, ischemic stroke albumin, neuroprotection",
author = "Hill, {Michael D.} and Martin, {Renee H.} and Palesch, {Yuko Y.} and Diego Tamariz and Waldman, {Bonnie D.} and Ryckborst, {Karla J.} and Moy, {Claudia S.} and Barsan, {William G.} and Myron Ginsberg",
year = "2011",
month = "6",
day = "1",
doi = "10.1161/STROKEAHA.110.610980",
language = "English",
volume = "42",
pages = "1621--1625",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The albumin in acute stroke part 1 trial

T2 - An exploratory efficacy analysis

AU - Hill, Michael D.

AU - Martin, Renee H.

AU - Palesch, Yuko Y.

AU - Tamariz, Diego

AU - Waldman, Bonnie D.

AU - Ryckborst, Karla J.

AU - Moy, Claudia S.

AU - Barsan, William G.

AU - Ginsberg, Myron

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background And Purpose- The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial. Methods- ALIAS is a multicenter, blinded, randomized controlled trial. Data on 434 subjects, comprising the ALIAS Part 1 subjects, were analyzed. We examined both the thrombolysis and nonthrombolysis cohorts combined and separately in a "target population" by excluding subjects who would not have been eligible for the ALIAS Part 2 Trial; the latter comprised patients >83 years of age, those with elevated baseline troponin values, and those with in-hospital stroke. We examined the differences in the primary composite outcome, defined as a modified Rankin Scale score of 0 to 1 and/or a National Institutes of Health Stroke Scale score of 0 to 1 at 90 days after randomization. Results- In the combined thrombolysis plus nonthrombolysis cohorts of the target population, 44.7% of subjects in the ALB group had a favorable outcome compared with 36.0% in the saline group (absolute effect size=8.7%; 95% CI, -2.2% to 19.5%). Among thrombolyzed subjects of the target population, 46.7% had a favorable outcome in the ALB group compared with 36.6% in the saline group (absolute effect size=10.1%; 95% CI, -2.0% to 20.0%). Conclusions- Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results.

AB - Background And Purpose- The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial. Methods- ALIAS is a multicenter, blinded, randomized controlled trial. Data on 434 subjects, comprising the ALIAS Part 1 subjects, were analyzed. We examined both the thrombolysis and nonthrombolysis cohorts combined and separately in a "target population" by excluding subjects who would not have been eligible for the ALIAS Part 2 Trial; the latter comprised patients >83 years of age, those with elevated baseline troponin values, and those with in-hospital stroke. We examined the differences in the primary composite outcome, defined as a modified Rankin Scale score of 0 to 1 and/or a National Institutes of Health Stroke Scale score of 0 to 1 at 90 days after randomization. Results- In the combined thrombolysis plus nonthrombolysis cohorts of the target population, 44.7% of subjects in the ALB group had a favorable outcome compared with 36.0% in the saline group (absolute effect size=8.7%; 95% CI, -2.2% to 19.5%). Among thrombolyzed subjects of the target population, 46.7% had a favorable outcome in the ALB group compared with 36.6% in the saline group (absolute effect size=10.1%; 95% CI, -2.0% to 20.0%). Conclusions- Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results.

KW - acute treatment

KW - adjuvant stroke therapy

KW - ischemic stroke albumin

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=79955370882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955370882&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.110.610980

DO - 10.1161/STROKEAHA.110.610980

M3 - Article

C2 - 21546491

AN - SCOPUS:79955370882

VL - 42

SP - 1621

EP - 1625

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -